{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:44:42Z","timestamp":1773251082416,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:00:00Z","timestamp":1792281600000},"content-version":"am","delay-in-days":351,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009023","name":"Precursory Research for Embryonic Science and Technology","doi-asserted-by":"publisher","award":["JPMJPR23R1"],"award-info":[{"award-number":["JPMJPR23R1"]}],"id":[{"id":"10.13039\/501100009023","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jiac.2025.102830","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T23:34:44Z","timestamp":1760571284000},"page":"102830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Retreatment or prolonged antiviral therapy in severe acute respiratory syndrome Coronavirus-2 infection among immunocompromised patients during 2022\u20132023: A nationwide claims-based cohort study in Japan"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2890-7256","authenticated-orcid":false,"given":"Shinya","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiko","family":"Ikeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuya","family":"Okushin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Kado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Kitaura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Okugawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0851-1887","authenticated-orcid":false,"given":"Takeya","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jiac.2025.102830_bib1","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMc2207519","article-title":"Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 subvariants","volume":"387","author":"Takashita","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jiac.2025.102830_bib2","doi-asserted-by":"crossref","first-page":"608","DOI":"10.7883\/yoken.JJID.2022.092","article-title":"Casirivimab\/imdevimab for active COVID-19 pneumonia which persisted for nine months in a patient with follicular lymphoma during Anti-CD20 therapy","volume":"75","author":"Nagai","year":"2022","journal-title":"Jpn J Infect Dis"},{"issue":"4","key":"10.1016\/j.jiac.2025.102830_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/pnasnexus\/pgaf085","article-title":"Clinical and molecular landscape of prolonged SARS-CoV-2 infection with resistance to remdesivir in immunocompromised patients","volume":"4","author":"Iriyama","year":"2025","journal-title":"PNAS Nexus"},{"issue":"7","key":"10.1016\/j.jiac.2025.102830_bib4","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1016\/S1473-3099(23)00815-0","article-title":"Persistent SARS-CoV-2 infection: significance and implications","volume":"24","author":"Machkovech","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.jiac.2025.102830_bib6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1159\/000523872","article-title":"COVID-19 in patients with hematologic malignancies: clinical manifestations, persistence, and immune response","volume":"145","author":"Gur","year":"2022","journal-title":"Acta Haematol"},{"issue":"1","key":"10.1016\/j.jiac.2025.102830_bib7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41408-023-00897-5","article-title":"Clinical and immunological characteristics of prolonged SARS-CoV-2 omicron infection in hematologic disease","volume":"13","author":"Ikeda","year":"2023","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.jiac.2025.102830_bib8","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/bjh.19143","article-title":"Prolonged shedding of viable SARS-CoV-2 in immunocompromised patients with haematological malignancies: a prospective study","volume":"204","author":"Ichikawa","year":"2024","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1016\/j.jiac.2025.102830_bib9","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1161\/CIRCULATIONAHA.120.052624","article-title":"Association of blood pressure classification using the 2017 American college of cardiology\/American heart association blood pressure guideline with risk of heart failure and atrial fibrillation","volume":"143","author":"Kaneko","year":"2021","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jiac.2025.102830_bib10","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/jgf2.422","article-title":"Data resource profile: JMDC claims database sourced from health insurance societies","volume":"22","author":"Nagai","year":"2021","journal-title":"J Gen Fam Med"},{"issue":"4","key":"10.1016\/j.jiac.2025.102830_bib13","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1093\/cid\/ciad474","article-title":"Unintended consequences: risk of opportunistic infections associated with long-term glucocorticoid therapies in adults","volume":"78","author":"Chastain","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jiac.2025.102830_bib14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/00003495-199958010-00009","article-title":"Rituximab","volume":"58","author":"Onrust","year":"1999","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.jiac.2025.102830_bib15","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-duration complete remissions of diffuse large B cell lymphoma after Anti-CD19 chimeric antigen receptor T cell therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.jiac.2025.102830_bib16","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/bjh.15722","article-title":"Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis","volume":"184","author":"Martinez-Calle","year":"2019","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.jiac.2025.102830_bib17","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.jiac.2025.102830_bib18","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1158\/2159-8290.CD-21-1033","article-title":"Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies","volume":"12","author":"Lee","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jiac.2025.102830_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.86","article-title":"Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma","volume":"5","author":"Saito","year":"2015","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.jiac.2025.102830_bib20","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1023\/A:1008309911008","article-title":"Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours","volume":"11","author":"Sch\u00f6ffski","year":"2000","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.jiac.2025.102830_bib21","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jiac.2022.01.014","article-title":"Persistent viral shedding of severe acute respiratory syndrome coronavirus 2 after treatment with bendamustine and rituximab: a case report","volume":"28","author":"Arai","year":"2022","journal-title":"J Infect Chemother"},{"issue":"9","key":"10.1016\/j.jiac.2025.102830_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.7861","article-title":"Prolonged SARS-CoV-2 infection during obinutuzumab and bendamustine treatment for follicular lymphoma: a case report","volume":"11","author":"Kambe","year":"2023","journal-title":"Clin Case Rep"},{"issue":"8","key":"10.1016\/j.jiac.2025.102830_bib23","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jiac.2025.102830_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae449","article-title":"Outcomes of antiviral retreatment for immunocompromised hosts with prolonged severe acute respiratory syndrome coronavirus 2 polymerase chain reaction positivity: a multicenter Australian retrospective case series","volume":"11","author":"Bond","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"731","key":"10.1016\/j.jiac.2025.102830_bib25","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk1599","article-title":"SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency","volume":"16","author":"Li","year":"2024","journal-title":"Sci Transl Med"},{"issue":"64","key":"10.1016\/j.jiac.2025.102830_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl4509","article-title":"Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2","volume":"6","author":"Israelow","year":"2021","journal-title":"Sci Immunol"},{"issue":"4","key":"10.1016\/j.jiac.2025.102830_bib27","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.immuni.2023.02.017","article-title":"SARS-CoV-2 breakthrough infection induces rapid memory and de novo T cell responses","volume":"56","author":"Koutsakos","year":"2023","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.jiac.2025.102830_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae449","article-title":"Outcomes of antiviral retreatment for immunocompromised hosts with prolonged severe acute respiratory syndrome Coronavirus 2 polymerase chain reaction positivity: a multicenter Australian retrospective case series","volume":"11","author":"Bond","year":"2024","journal-title":"Open Forum Infect Dis"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25002272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25002272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T22:00:28Z","timestamp":1773180028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X25002272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1341321X25002272"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102830","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retreatment or prolonged antiviral therapy in severe acute respiratory syndrome Coronavirus-2 infection among immunocompromised patients during 2022\u20132023: A nationwide claims-based cohort study in Japan","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102830","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102830"}}